2026 Q1 -tulosraportti
76 päivää sitten
‧44 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 12.3. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 22.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·18 t sittenThe banks say buy to the stock! ATP and others who would not sell at a much higher price should buy up now!
As I wrote 2 days ago: Because ATP must also ensure good diversification in its portfolio. Novo has probably fallen sharply compared to ATP's purchase price. So there is room to buy further. The same has not happened with BAVA, because it was not bought at the short-lived peak of 250 kr, but much earlier and at a lower price. And by the way, ATP's management probably doesn't need to put themselves in a vulnerable position - when there's plenty else to invest in. But I'm buying now, where the share is down to the level of the price before the takeover bid. More
·1 päivä sitten · MuokattuI understand that technical analysis points a bit to what my daughter would call "lame" in the short term (not that I myself am a big expert in technical analysis). Despite this, I am still close to buying BAVA again for her more long-term portfolio. I have on many occasions had success with large gains in this stock. And I think it is now being beaten down to the bottom again. My considerations are, as those who are in BAVA know well; a) geopolitical unrest provides stable future earnings on mpox, and occasional boosts from mpox outbreaks, and b) the travel vaccines that BAVA bought in 2019/20 seem to be growing steadily in earnings - and relatively good economic key figures in the USA will surely mean more travelers etc etc (even though jet fuel is naturally a negative factor at present). I understand that several experts see a potential of 3-4 billion annually for the chikungunya vaccine (and the only competitor is the small flimsy French company with bad side effects). If this is correctly assumed, and the vaccine is not even rolled out in e.g. Brazil - then we are surely looking forward to a "blue ocean" scenario? I just can't really figure out what "bulk-vaccine-demand" there is at a governmental level in South and Latin America etc - does anyone have knowledge about this? Could Bill Gates not also consider expanding his philanthropic vaccine program to developing countries with this vaccine? (However, I am not familiar with the selection criteria for this program?) In addition, there is probably a possibility for yet another acquisition scenario (where I fortunately sold last time).There will hardly be a takeover bid in the near future, unless someone has already accepted the price ATP wants to sell at. We don't know that price and won't be told it before a potential takeover bid comes (if it comes at all.) But we know the floor price for any potential future takeover bid and don't need to be nervous that the company will be sold at a lower price. That's always good to know when buying in. But therefore the share can still fall further, even if it is cheap relative to earnings.
·3 päivää sittenBavarinn currently has a market capitalization of 14 Mia, and an equity of approx. 13 Mia. I believe Bavarian owns approx 4% of the shares. Does anyone know why Bavarian has chosen to have such a large cash holding? If the money is not to be used to grow the company, they can buy back their own shares. This would stop the bleeding for us shareholders. Does anyone know when Chaplin stops.
·3 päivää sittenHasn't ATP noticed the fall? When 250 was too cheap, why haven't they supplemented at this level?Yes, but look what they have done in Novo, and by buying a bit more at this level, and thereby lowering the average price, it might be possible to get rid of a bit more, because aren't we close to trading it close to its intrinsic value, and how many stocks that have come with an upward revision, are traded at that level.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
76 päivää sitten
‧44 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·18 t sittenThe banks say buy to the stock! ATP and others who would not sell at a much higher price should buy up now!As I wrote 2 days ago: Because ATP must also ensure good diversification in its portfolio. Novo has probably fallen sharply compared to ATP's purchase price. So there is room to buy further. The same has not happened with BAVA, because it was not bought at the short-lived peak of 250 kr, but much earlier and at a lower price. And by the way, ATP's management probably doesn't need to put themselves in a vulnerable position - when there's plenty else to invest in. But I'm buying now, where the share is down to the level of the price before the takeover bid. More
- ·1 päivä sitten · MuokattuI understand that technical analysis points a bit to what my daughter would call "lame" in the short term (not that I myself am a big expert in technical analysis). Despite this, I am still close to buying BAVA again for her more long-term portfolio. I have on many occasions had success with large gains in this stock. And I think it is now being beaten down to the bottom again. My considerations are, as those who are in BAVA know well; a) geopolitical unrest provides stable future earnings on mpox, and occasional boosts from mpox outbreaks, and b) the travel vaccines that BAVA bought in 2019/20 seem to be growing steadily in earnings - and relatively good economic key figures in the USA will surely mean more travelers etc etc (even though jet fuel is naturally a negative factor at present). I understand that several experts see a potential of 3-4 billion annually for the chikungunya vaccine (and the only competitor is the small flimsy French company with bad side effects). If this is correctly assumed, and the vaccine is not even rolled out in e.g. Brazil - then we are surely looking forward to a "blue ocean" scenario? I just can't really figure out what "bulk-vaccine-demand" there is at a governmental level in South and Latin America etc - does anyone have knowledge about this? Could Bill Gates not also consider expanding his philanthropic vaccine program to developing countries with this vaccine? (However, I am not familiar with the selection criteria for this program?) In addition, there is probably a possibility for yet another acquisition scenario (where I fortunately sold last time).There will hardly be a takeover bid in the near future, unless someone has already accepted the price ATP wants to sell at. We don't know that price and won't be told it before a potential takeover bid comes (if it comes at all.) But we know the floor price for any potential future takeover bid and don't need to be nervous that the company will be sold at a lower price. That's always good to know when buying in. But therefore the share can still fall further, even if it is cheap relative to earnings.
- ·3 päivää sittenBavarinn currently has a market capitalization of 14 Mia, and an equity of approx. 13 Mia. I believe Bavarian owns approx 4% of the shares. Does anyone know why Bavarian has chosen to have such a large cash holding? If the money is not to be used to grow the company, they can buy back their own shares. This would stop the bleeding for us shareholders. Does anyone know when Chaplin stops.
- ·3 päivää sittenHasn't ATP noticed the fall? When 250 was too cheap, why haven't they supplemented at this level?Yes, but look what they have done in Novo, and by buying a bit more at this level, and thereby lowering the average price, it might be possible to get rid of a bit more, because aren't we close to trading it close to its intrinsic value, and how many stocks that have come with an upward revision, are traded at that level.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 12.3. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 22.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 |
2026 Q1 -tulosraportti
76 päivää sitten
‧44 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 12.3. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 22.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·18 t sittenThe banks say buy to the stock! ATP and others who would not sell at a much higher price should buy up now!As I wrote 2 days ago: Because ATP must also ensure good diversification in its portfolio. Novo has probably fallen sharply compared to ATP's purchase price. So there is room to buy further. The same has not happened with BAVA, because it was not bought at the short-lived peak of 250 kr, but much earlier and at a lower price. And by the way, ATP's management probably doesn't need to put themselves in a vulnerable position - when there's plenty else to invest in. But I'm buying now, where the share is down to the level of the price before the takeover bid. More
- ·1 päivä sitten · MuokattuI understand that technical analysis points a bit to what my daughter would call "lame" in the short term (not that I myself am a big expert in technical analysis). Despite this, I am still close to buying BAVA again for her more long-term portfolio. I have on many occasions had success with large gains in this stock. And I think it is now being beaten down to the bottom again. My considerations are, as those who are in BAVA know well; a) geopolitical unrest provides stable future earnings on mpox, and occasional boosts from mpox outbreaks, and b) the travel vaccines that BAVA bought in 2019/20 seem to be growing steadily in earnings - and relatively good economic key figures in the USA will surely mean more travelers etc etc (even though jet fuel is naturally a negative factor at present). I understand that several experts see a potential of 3-4 billion annually for the chikungunya vaccine (and the only competitor is the small flimsy French company with bad side effects). If this is correctly assumed, and the vaccine is not even rolled out in e.g. Brazil - then we are surely looking forward to a "blue ocean" scenario? I just can't really figure out what "bulk-vaccine-demand" there is at a governmental level in South and Latin America etc - does anyone have knowledge about this? Could Bill Gates not also consider expanding his philanthropic vaccine program to developing countries with this vaccine? (However, I am not familiar with the selection criteria for this program?) In addition, there is probably a possibility for yet another acquisition scenario (where I fortunately sold last time).There will hardly be a takeover bid in the near future, unless someone has already accepted the price ATP wants to sell at. We don't know that price and won't be told it before a potential takeover bid comes (if it comes at all.) But we know the floor price for any potential future takeover bid and don't need to be nervous that the company will be sold at a lower price. That's always good to know when buying in. But therefore the share can still fall further, even if it is cheap relative to earnings.
- ·3 päivää sittenBavarinn currently has a market capitalization of 14 Mia, and an equity of approx. 13 Mia. I believe Bavarian owns approx 4% of the shares. Does anyone know why Bavarian has chosen to have such a large cash holding? If the money is not to be used to grow the company, they can buy back their own shares. This would stop the bleeding for us shareholders. Does anyone know when Chaplin stops.
- ·3 päivää sittenHasn't ATP noticed the fall? When 250 was too cheap, why haven't they supplemented at this level?Yes, but look what they have done in Novo, and by buying a bit more at this level, and thereby lowering the average price, it might be possible to get rid of a bit more, because aren't we close to trading it close to its intrinsic value, and how many stocks that have come with an upward revision, are traded at that level.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt